

Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle

Authorised

- Bovine parainfluenza virus 3, strain INT2-2013, Live
- Bovine respiratory syncytial virus, strain Jencine-2013, Live

Product identification

Medicine name:

Bovilis INtranasal RSP Live nasal spray, lyophilisate and solvent for suspension for cattle

Bovilis RSP live vet. Nässpray, frystorkat pulver och vätska till suspension

Active substance:

Bovine parainfluenza virus 3, strain INT2-2013, Live

Bovine respiratory syncytial virus, strain Jencine-2013, Live

Target species:

Cattle

Route of administration:

Nasal use

Product details

Active substance and strength:

Bovine parainfluenza virus 3, strain INT2-2013, Live
4.80 log₁₀ 50% tissue culture infectious dose / 2.00 millilitre(s)

Bovine respiratory syncytial virus, strain Jencine-2013, Live
5.00 log₁₀ 50% tissue culture infectious dose / 2.00 millilitre(s)

Pharmaceutical form:

Nasal spray, suspension

Withdrawal period by route of administration:**Nasal use:**

-

Cattle

- Meat and offal. no withdrawal period zero days

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AD07

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Sweden

Package description:

Available only in Swedish
Available only in Swedish

Cardboard box with 10 doses of lyophilisate and cardboard box with 20 ml solvent
Cardboard box with 20 doses of lyophilisate and 40 ml of solvent

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

23/07/2019

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

Swedish Medical Products Agency

Authorisation number:

57927

Date of authorisation status change:

23/07/2019

Reference member state:

Netherlands

Procedure number:

NL/V/0257/001

Concerned member states:

Austria Belgium Bulgaria Croatia Cyprus Czechia Denmark Estonia Finland
France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania
Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents